In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Celso Arango
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Celso Arango

RESEARCHER INFORMATION
First Name:Celso
Last Name:Arango
Title:Dr
Advanced Degrees:MD PhD
Affiliation:Hospital General Universitario Gregorio Marañón
Department:Psychiatry
Street Address 1:Ibiza 43
City:Madrid
State/Province:Madrid
Zip/Postal Code:28009
Country/Territory:Spain
Phone:+34914265006
Fax:+34914265004
Email Address: carango@hggm.es
Disclosure:
(view policy) 
Member reports the following financial or other potential conflicts of interest: [Last Modified: 16 August 2012]

Dr. Arango. has been a consultant to or has received honoraria or grants from Abbot, Astra Zeneca, Bristol-Myers Squibb, Caja Navarra, CIBERSAM, Fundación Alicia Koplowitz, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier and Schering Plough.
Clinical Interests:
Neurodevelopmental disorders (e.g., 22q11 deletion syndromes), Schizophrenia, Autism spectrum disorders (pervasive developmental disorders), Bipolar disorder
Research Focus:
Brain imaging, Neuroanatomy/Systems Neuroscience, Neurodevelopment, Clinical trials, Glutamatergic transmission, Animal models, Pharmacology, Phenomenology/diagnosis
Work Sector(s):
Research institute, Medical hospital
Web Sites:
Personal: www.ua.hggm.es
Professional: www.cibersam.es
Reasearcher Bio
Academic Appointments

1999-2000 Attending Psychiatrist
Hospital General Universitario Gregorio Marañón
Madrid, Spain
1999-2005 Volunteer Adjunct Assistant Professor
University of Maryland School of Medicine
1999-2008 Associate Professor of Psychiatry
Complutense University of Madrid, Madrid, Spain
2000-2012 Head of Adolescent Psychiatric Unit
Hospital General Universitario Gregorio Marañón
Madrid, Spain
2005-present Volunteer Associate Professor of Psychiatry
University of Maryland School of Medicine
2009-present Associate Professor of Psychiatry
Complutense University of Madrid, Madrid, Spain
2012-present Head of Department
Department of Child and Adolescent Psychiatry
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Top Papers
Arango, C.; Rapado Castro, M.; Reig, S.; Castro-Fornieles, J.; González-Pinto, A.; Otero Cuesta, S.; Baeza, I.; Moreno, C.; Graell, M.; Janssen, J.; Parellada, M.; Moreno, D.; Bargalló, N.; Desco, M. Progressive brain changes in children and adolescents with first-episode psychosis. Archives of General Psychiatry, 69(1):16-26, 2012. (I.F.: 12.016).

Merchán-Naranjo, J.; Mayoral, M.; Rapado-Castro, M.; Llorente, C.; Boada, L.; Arango, C.; Parellada, M. Estimation of the Intelligence Quotient Using Wechsler Intelligence Scales in Children and Adolescents with Asperger Syndrome. Journal of Autism and Developmental Disorders, 42(1): 116-22, 2012. (I.F.: 3.341).

Parellada, M.; Moreno, C.; Mac-Dowell, K.; Leza, JC.; Giraldez, M.; Bailón, C.; Castro, C.; Miranda-Azpiazu, P.; Fraguas, D.; Arango, C. Plasma antioxidant capacity is reduced in Asperger syndrome. Journal of Psychiatry Research, 46(3):394-401, 2012. (I.F.: 4.664).

Janssen, J.; Aleman, Y.; Reig, S.; Schnack, H.; Parellada, M.; Graell, M.; Moreno, C.; Moreno, MD.; Mateos-Pérez, JM.; Udias, JM.; Arango, C.; Desco, M. Regional specificity of thalamic volume deficits in male adolescents with early-onset psychosis. British Journal of Psychiatry, 200: 30-6, 2012. (I.F.: 6.619).

Mayoral, M.; Bombín, I.; Castro-Fornieles, J.; González-Pinto, A.; Otero, S.; Parellada, M.; Moreno, D.; Baeza, I.; Graell, M.; Rapado, M.; Arango, C. Longitudinal study of neurological soft signs in first-episode early-onset psychosis. Journal of Child Psychology and Psychiatry, 53(3):323-31, 2012. (I.F.: 4.281).

Bobes, J.; Arango, C.; Aranda, P.; Carmena, R.; García-García, M.; Rejas, J.; on behalf of the CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study. European Psychiatry, 27(4): 267-274, 2012. (I.F.: 2.766).

Fischer, BA.; Keller, WR.; Arango, C.; Pearlson, GD.; McMahon, RP.; Meyer, WA.; Francis, A.; Kirkpatrick, B.; Carpenter, WT.; Buchanan, RW. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophrenia Research, 136(1-3):51-4, 2012. (I.F.: 4.748).

Moreno, C.; Hasin, DS.; Arango, C.; Oquendo, MA.; Vieta, E.; Liu, S.; Grant, BF.; Blanco, C. Depression in Bipolar versus Major Depression Disorder: Results from the National Epidemiological Survey on Alcohol and Related Conditions. Bipolar Disorders, 14(3): 271-82, 2012. (I.F.: 5.289).

Fraguas, D.; Gonzalez-Pinto, A.; Micó, JA.; Reig, S.; Parellada, M.; Martínez-Cengotitabengoa, M.; Castro-Fornieles, J.; Rapado-Castro, M.; Baeza, I.; Janssen, J.; Desco, M.; Leza, JC.; Arango, C. Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophrenia Research, 137(1-3):58-65, 2012. (I.F.: 4.748).

Nuevo, R.; Chatterji, S.; Verdes, E.; Naidoo, N.; Arango, C.; Ayuso-Mateos, JL The Continuum of Psychotic Symptoms in the General Population: A Cross-national Study. Schizophrenia Bulletin, 38(3):475-85, 2012. (I.F.: 8.800).

Pina-Camacho, L.; Villero, S.; Fraguas, D.; Boada, L.; Janssen, J.; Navas-Sánchez, FJ.; Mayoral, M.; Llorente, C.; Arango, C.; Parellada, M. Autism Spectrum Disorder: Does Neuroimaging Support the DSM-5 Proposal for a Symptom Dyad? A Systematic Review of Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Studies. Journal of Autism and Developmental Disorders, 42(7):1326-41, 2012. (I.F.: 3.341).
If resources were not limited, what research projects would you pursue?
Large cohort studies starting in pregnancy
What is your leading hypothesis?
Many neurodevelopment disorders end up with a common final pathway that produces delusions and hallucinations. Schizophrenia is an artificial construct.
What piece of missing evidence would help prove it?
Large epidemiological studies with GxE data



Research Participants
Collaborators
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright